Post-operative proton radiotherapy for thymus tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the effectiveness and side effects of proton radiotherapy administered after surgery for patients with locally advanced thymus epithelial tumors. Patients who have undergone R0 resection will receive a specific dosage of proton irradiation, while those with R1 resection will receive a higher dosage. Additionally, participants will undergo a regimen of platinum-based chemotherapy prior to radiotherapy. The study aims to measure progression-free survival and overall survival rates, along with assessing the associated toxicities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with stage II-III (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiation therapy, who have undergone radical surgery and have a definite pathological diagnosis, and undergone surgery for R0 (no microscopic residual disease) or R1 (microscopic residual disease) resection, and have indication of postoperative radiation therapy.
* Sign informed consent.
* Between the ages of 18 and 70.
* ECOG general status score of 0-2.
* The expected survival is at least 6 months.
* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1\>25%, DLCO\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \<1.5 times the upper limit of normal value, and AST, ALT\<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein \<2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.

Exclusion Criteria:

* Complicated with other malignant tumors that have not been controlled.
* Have large quantity of pleural or pericardial effusion.
* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.
* Chest radiation therapy or radioactive particle implantation history.
* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.
* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.
* A history of mental illness may hinder the completion of treatment.
* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.
* Other circumstances that the physician considers inappropriate to participate in clinical study.

Where it's running

• Shanghai Proton and Heavy Ion Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jingfang Mao, PHD — Shanghai Proton and Heavy Ion Center
• Study coordinator: Jing Li
• Email: jing.li@sphic.org.cn
• Phone: 86-21-38296678

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ozone therapy for refractory pain and quality of life in cancer patients

  This study looks at whether adjuvant ozone therapy can improve quality of life for adults with difficult-to-treat cancer-related symptoms referred to a palliative pain unit.

  Recruiting Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas · NCT07325851

• Gut microbiome in gynecologic cancer patients with pelvic toxicity

  This study looks at whether gut bacteria profiles relate to pelvic toxicity after cancer treatment and how rectal ozone therapy might affect the gut microbiome and symptoms in women with gynecologic tumors.

  Recruiting at 2 sites Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas and 1 other locations · NCT07259681

• Proton radiation with tremelimumab and durvalumab for BCLC stage B/C hepatocellular carcinoma

  This will test whether adding precise proton radiation to tremelimumab plus durvalumab helps people with unresectable BCLC stage B or C hepatocellular carcinoma.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999694

• Curative chest re‑irradiation for thoracic cancers

  This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.

  Recruiting University of Aarhus · Aarhus, Jutland · NCT06950073

• First-line bevacizumab versus dexamethasone for symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  This trial will test whether first-line bevacizumab or dexamethasone works better at reducing symptoms in adults with symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  Recruiting at 5 sites Phase 3 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06888817

• Evaluating the effects of radiotherapy in pediatric and adult patients with childhood cancers

  This study looks at how radiation therapy affects both kids and adults who had childhood cancers, checking for any side effects and how well it works over time.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT06639165

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.